Skip to main content
$79.46 $0.63 (0.8%)

04:00 PM EST on 01/25/22

Merck & Co., Inc. (NYSE:MRK)

CAPS Rating: 4 out of 5

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.

Current Price $79.46 Mkt Cap $199.1B
Open $78.42 P/E Ratio 27.94
Prev. Close $79.46 Div. (Yield) $2.76 (3.5%)
Daily Range $77.78 - $79.78 Volume 13,662,385
52-Wk Range $68.38 - $91.40 Avg. Daily Vol. 14,277,620

Caps

How do you think NYSE:MRK will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,726 Outperform
221 Underperform
 

All-Star Players

458 Outperform
30 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:MRK Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

DRRAB (29.68)
Submitted October 02, 2021

anti-viral pill for covid

bryank2000 (82.24)
Submitted August 14, 2011

Terrible leadership + atrocious decision making has fostered a culture of fear and indifference. Not sure how that bolsters the pipeline.

Recent Community Commentary

Read the most recent pitches from players about MRK.

Recs

1
Member Avatar DRRAB (29.68) Submitted: 10/1/2021 9:42:30 PM : Outperform Start Price: $84.17 NYSE:MRK Score: -5.96

anti-viral pill for covid

Recs

1
Member Avatar publius200 (< 20) Submitted: 10/1/2021 1:29:59 PM : Outperform Start Price: $82.10 NYSE:MRK Score: -3.71

Introduction of Covid pill will increase stock price.

Recs

1
Member Avatar BOHICA101 (< 20) Submitted: 9/28/2021 12:31:44 PM : Outperform Start Price: $73.43 NYSE:MRK Score: +8.09

This stock has potential to take off.

Merck partnered with Ridgeback Biotherapeutics Ridgeback Biotherapeutics as they hold the rights to molnupiravir.
Their drug, molnupiravir, is one of two powerful medicines to treat COVID-19 that are nearing the end of clinical testing. Research suggested the compound could make it harder for the virus to replicate itself by interrupting the RNA polymerase enzyme, which acts like a copy machine for the viral genome. In various academic labs, molnupiravir has demonstrated activity against flu and many different types of coronavirus, including MERS and the common cold.
The hope is that it can stop the virus in its tracks, before it can replicate uncontrollably and cause a person to become more sick.

The U.S. government has agreed to purchase 1.7 billion doses at a cost of $1.2 billion if it passes Phase 3 and this would just be the beginning.
Also,
Merck is Reportedly Close to Buying Acceleron Pharma for 11 billion

Leaderboard

Find the members with the highest scoring picks in MRK.

Score Leader

TrackTobinSmith

TrackTobinSmith (< 20) Score: +174.33

The Score Leader is the player with the highest score across all their picks in MRK.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
kaliblade 85.22 2/12/2009 Underperform 3W $18.92 +319.93% +438.35% +118.42 0 Comment
prettymeadow < 20 3/20/2009 Underperform 3M $17.51 +353.85% +457.53% +103.68 0 Comment
dbwhiz57 < 20 12/17/2007 Underperform 1Y $36.83 +115.75% +213.83% +98.08 0 Comment
JoeySly 88.54 3/6/2009 Underperform 3W $14.71 +440.36% +537.31% +96.95 0 Comment
fraley250r < 20 1/7/2008 Underperform NS $35.36 +124.71% +219.38% +94.67 0 Comment
bubba1986 < 20 1/23/2008 Underperform 3W $30.69 +158.95% +252.23% +93.28 0 Comment
fordfest99 34.00 3/26/2009 Underperform 3Y $18.18 +337.10% +429.84% +92.75 0 Comment
buckywildcat < 20 1/26/2009 Underperform 1Y $18.17 +337.29% +429.07% +91.79 0 Comment
stockpickeraz 26.09 1/16/2009 Underperform 5Y $18.29 +334.46% +423.29% +88.83 0 Comment
TMFSpeck 70.50 2/12/2010 Underperform 5Y $25.06 +217.04% +304.27% +87.24 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MRK.